Transpire Bio begins human trials for inhaled asthma and COPD treatment

Transpire Bio has begun human trials for its inhaled drug aimed at treating asthma and chronic obstructive pulmonary disease (COPD). This marks a significant milestone for the company as it advances its inhalation medicine program. Asthma affected 262 million people globally in 2019, while COPD was the third leading cause of death, claiming 3.2 million lives. Transpire Bio aims to address these health issues with its innovative inhalation therapies. The company is developing various inhalation technologies, including dry powder and metered-dose inhalers. This initiative reflects Transpire Bio's commitment to improving access to essential treatments for serious diseases.